Seres Therapeutics Inc (NASDAQ: MCRB) kicked off on Friday, up 2.67% from the previous trading day, before settling in for the closing price of $0.97. Over the past 52 weeks, MCRB has traded in a range of $0.54-$6.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 386.36% over the last five years. While this was happening, its average annual earnings per share was recorded -5.30%. With a float of $119.77 million, this company’s outstanding shares have now reached $135.04 million.
The firm has a total of 233 workers. Let’s measure their productivity.
Seres Therapeutics Inc (MCRB) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Seres Therapeutics Inc is 20.92%, while institutional ownership is 41.44%. The most recent insider transaction that took place on May 15 ’24, was worth 2,289. In this transaction CEO and President of this company sold 2,435 shares at a rate of $0.94, taking the stock ownership to the 140,698 shares. Before that another transaction happened on May 15 ’24, when Company’s insider sold 1,090 for $0.94, making the entire transaction worth $1,025. This insider now owns 75,734 shares in total.
Seres Therapeutics Inc (MCRB) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -5.30% per share during the next fiscal year.
Seres Therapeutics Inc (NASDAQ: MCRB) Trading Performance Indicators
Take a look at Seres Therapeutics Inc’s (MCRB) current performance indicators. Last quarter, stock had a quick ratio of 1.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Seres Therapeutics Inc (MCRB)
Analysing the last 5-days average volume posted by the [Seres Therapeutics Inc, MCRB], we can find that recorded value of 2.05 million was lower than the volume posted last year of 4.71 million. As of the previous 9 days, the stock’s Stochastic %D was 49.31%. Additionally, its Average True Range was 0.10.
During the past 100 days, Seres Therapeutics Inc’s (MCRB) raw stochastic average was set at 30.46%, which indicates a significant decrease from 65.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.39% in the past 14 days, which was lower than the 117.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8413, while its 200-day Moving Average is $1.4266. Now, the first resistance to watch is $1.0533. This is followed by the second major resistance level at $1.1067. The third major resistance level sits at $1.1433. If the price goes on to break the first support level at $0.9633, it is likely to go to the next support level at $0.9267. Should the price break the second support level, the third support level stands at $0.8733.
Seres Therapeutics Inc (NASDAQ: MCRB) Key Stats
The company with the Market Capitalisation of 151.45 million has total of 151,448K Shares Outstanding. Its annual sales at the moment are 126,330 K in contrast with the sum of -113,720 K annual income. Company’s last quarter sales were recorded 60 K and last quarter income was -41,250 K.
